Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0310492 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Fareeaa Ashar und 2 weiteren Autor:innen. Beteiligte Einrichtung: Research Scholar, Department of Pharmacy, Annamalai University, Annamalainagar, Chidambaram, Tamil Nadu, India. Hauptthemen laut MEDLINE: Adenine, Piperidines, Biological Availability, Liposomes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Khalid University.
Abstract (Originalsprache)
Liposils, synthesized via the liposome templating method, offer a promising strategy for enhancing liposome stability by employing a silica coating. This study focuses on the development of nanocarriers utilizing silica-coated nanoliposomes for encapsulating the poorly water-soluble drug, ibrutinib. Ibrutinib-loaded nanoliposomes were meticulously formulated using the reverse-phase evaporation technique, serving as templates for silica coating, resulting in spherical liposils with an average size of approximately 240 nanometers. Comprehensive characterization of the liposil’s physical and chemical properties was conducted using various analytical methods, including dynamic light scattering, transmission electron microscopy, Fourier-transform infrared spectroscopy, and X-ray diffraction analysis. Liposils demonstrated superior performance compared to ibrutinib-loaded nanoliposomes, showing sustained drug release profiles in simulated intestinal fluids and resistance to simulated gastric fluid, as confirmed by dissolution studies. Moreover, ibrutinib liposils exhibited a significant increase in half-life (4.08-fold) and notable improvement in bioavailability (3.12-fold) compared to ibrutinib suspensions, as determined by pharmacokinetic studies in rats. These findings underscore the potential of liposils as nanocarriers for orally delivering poorly water-soluble drugs, offering enhanced stability and controlled release profiles, thereby improving bioavailability prospects and therapeutic efficacy. This approach holds promise for addressing challenges associated with the oral administration of drugs with limited solubility, thereby advancing drug delivery technologies and clinical outcomes in pharmaceutical research and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Scholar, Department of Pharmacy, Annamalai University, Annamalainagar, Chidambaram, Tamil Nadu, India.
- Department of Clinical Pharmacy, College of Pharmacy, King Khalid University, Abha, Kingdom of Saudi Arabia.
ORCID-Profile: Fareeaa Ashar, S Selvamuthukumar
Förderung
- King Khalid University
Zitieren
APA
Ashar, F., Mohammed, A. A. S., & Selvamuthukumar, S. (2024). Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system. PLOS ONE. https://doi.org/10.1371/journal.pone.0310492
Vancouver
Ashar F, Mohammed AAS, Selvamuthukumar S. Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system. PLOS ONE. 2024. doi:10.1371/journal.pone.0310492
BibTeX
@article{Ashar2024,
author = {Ashar, Fareeaa and Mohammed, Asif Ansari Shaik and Selvamuthukumar, S},
title = {Enhancement of oral bioavailability of ibrutinib using a liposil nanohybrid delivery system},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0310492}
}
EUVIMED